Pharmena S.A.
PHR.WA · WSE
12/31/2024 | 12/31/2023 | 12/31/2022 | 12/31/2021 | |
|---|---|---|---|---|
| Revenue | PLN 268 | PLN 9,837 | PLN 299 | PLN 15,213 |
| % Growth | -97.3% | 3,190% | -98% | – |
| Cost of Goods Sold | PLN 70 | PLN 3,994 | PLN 8,687 | PLN 7,381 |
| Gross Profit | PLN 198 | PLN 5,843 | PLN 10,335 | PLN 7,832 |
| % Margin | 73.9% | 59.4% | 3,456.5% | 51.5% |
| R&D Expenses | PLN 10 | PLN 0 | PLN 153 | PLN 133 |
| G&A Expenses | PLN 2,952 | PLN 3,588 | PLN 3,225 | PLN 4,677 |
| SG&A Expenses | PLN 3,575 | PLN 7,875 | PLN 3,840 | PLN 12,016 |
| Sales & Mktg Exp. | PLN 623 | PLN 4,287 | PLN 615 | PLN 7,339 |
| Other Operating Expenses | PLN 10 | -PLN 36,903 | PLN 6,861 | -PLN 308 |
| Operating Expenses | PLN 3,595 | -PLN 29,028 | PLN 10,854 | PLN 11,841 |
| Operating Income | -PLN 3,397 | PLN 34,871 | -PLN 508 | -PLN 3,983 |
| % Margin | -1,267.5% | 354.5% | -169.9% | -26.2% |
| Other Income/Exp. Net | PLN 840 | -PLN 15 | -PLN 904 | -PLN 474 |
| Pre-Tax Income | -PLN 2,557 | PLN 34,856 | -PLN 4,954 | -PLN 4,457 |
| Tax Expense | -PLN 1,295 | PLN 5,908 | PLN 204 | PLN 182 |
| Net Income | -PLN 1,262 | PLN 28,941 | -PLN 1,570 | -PLN 4,592 |
| % Margin | -470.9% | 294.2% | -525.1% | -30.2% |
| EPS | -0.11 | 2.6 | -0.14 | -0.41 |
| % Growth | -104.2% | 1,957.1% | 65.9% | – |
| EPS Diluted | -0.11 | 2.6 | -0.14 | -0.41 |
| Weighted Avg Shares Out | 11,138 | 11,138 | 11,138 | 11,110 |
| Weighted Avg Shares Out Dil | 11,138 | 11,138 | 11,138 | 11,110 |
| Supplemental Information | – | – | – | – |
| Interest Income | PLN 842 | PLN 430 | PLN 656 | PLN 265 |
| Interest Expense | PLN 0 | PLN 530 | PLN 722 | PLN 265 |
| Depreciation & Amortization | PLN 21 | PLN 325 | PLN 561 | PLN 626 |
| EBITDA | -PLN 3,382 | PLN 35,552 | -PLN 129 | -PLN 3,515 |
| % Margin | -1,261.9% | 361.4% | -43.1% | -23.1% |